SAFE Notes vs Convertible Notes: One Protects Founders, One Protects Investors — Know Which Is Which

SAFE Notes vs Convertible Notes: One Protects Founders, One Protects Investors — Know Which Is Which

Y Combinator created the SAFE in 2013 to make fundraising faster. It worked. It also shifted ALL the downside risk to founders and handed investors a perpetual free option with zero accountability. Twelve years later, most founders still don't understand the trade-off they're making when they sign one.

I've watched this play out across dozens of cap tables. A founder raises $500K across four SAFEs, thinks they've been smart and capital-efficient, then hits a Series A and finds out they own 12 percentage points less of their company than they expected. The math was always there. Nobody showed them how to run it.

The Surface Story vs. What's Actually Happening

Here's what the SAFE sales pitch sounds like: no interest, no maturity date, no repayment risk. The founder-friendly instrument that replaced the old, expensive convertible note. Fast to close, cheap to execute, and easy to explain to investors at a pitch meeting.

Every word of that is technically true. Here's what they don't tell you.

No maturity date means no forcing function. A convertible note investor has a clock ticking — 12 to 24 months, then either the note converts to equity or they demand repayment. That's accountability. That's an investor with skin in the game who needs your company to succeed or get to a priced round. A SAFE investor has no such constraint. They can hold that instrument forever, collect SAFEs from 30 different companies like lottery tickets, and wait. Zero downside, no accountability, no reason to call you and ask how things are going.

SAFEs are investor-friendly instruments dressed in founder-friendly clothes. The faster close and cheaper legal fees benefit you on Day 1. Everything after that benefits them.

How These Instruments Actually Work

A SAFE — Simple Agreement for Future Equity — is not debt. It's a contract that gives an investor the right to receive equity when a future priced round, acquisition, or IPO occurs. No interest accrues. No repayment is owed if nothing happens. If your company shuts down in year three without ever pricing a round, the SAFE holder gets nothing — but they also lost nothing they were counting on.

A convertible note is a loan. An actual promissory note with an interest rate (typically 2–8% annually), a maturity date (usually 12–24 months), and a legal obligation. If you don't raise a priced round before maturity, the noteholder can demand repayment — principal plus accrued interest. Most don't exercise that right because a dead startup can't pay them back anyway. But the option exists, and it changes the dynamic.

Both instruments typically include a valuation cap and a discount rate. The cap limits the price per share an investor pays when their instrument converts. The discount gives them additional upside relative to new investors in the priced round. Those terms exist in both structures — that's not where the difference lives.

Head-to-Head: SAFE vs. Convertible Note

Feature	SAFE Note	Convertible Note
Instrument type	Agreement (not debt)	Debt (promissory note)
Interest rate	0%	2–8% per year
Maturity date	None	12–24 months (avg. 18)
Valuation cap	Yes (typically $5M–$20M)	Yes (typically $5M–$20M)
Discount rate	Yes (typically 10–20%)	Yes (typically 10–20%)
Complexity	Low (4-page template)	Medium-high (8–12 pages)
Legal setup cost	$0–$2,000 (YC template free)	$5,000–$15,000
Time to close	1–2 weeks	4–8 weeks
Investor downside protection	None	High (repayment right at maturity)
Dilution clarity	Low (unknown until conversion)	Moderate (clearer at signing)

The Post-Money SAFE Trap Most Founders Walk Right Into

In 2018, YC introduced the post-money SAFE to fix an ambiguity problem. Before 2018, pre-money SAFEs had fuzzy math around how many shares an investor actually received — because the denominator kept changing as more SAFEs were issued. The post-money structure fixed that. It also created a new problem.

Here's the trap. A post-money SAFE with a $10M cap means the total company value — including the conversion — equals $10M at the time of the round. Sounds clean. But the option pool is included in that $10M.

Run the math on a $10M post-money SAFE with a 10% option pool:

• Post-money cap: $10M
• Option pool included in the cap: 10% = $1M in reserved value
• Remaining value for founders and this investor: $9M
• The SAFE investor gets $X / $9M of the company — not $X / $10M

You expected to give up 10% on a $1M SAFE (1/10 of $10M). You're actually giving up 11.1% (1/9 of $9M). That's an extra 1.11 percentage points per SAFE. Sign four SAFEs with a 10% option pool each, and you've hemorrhaged an extra 4.4% of your company before you've closed a single institutional round.

The fix is simple: negotiate the option pool outside the SAFE cap. Not every investor will accept it, but experienced founders push for it every time. If your investor won't agree, at minimum you need to know the exact dilution hit you're taking before you sign.

The SAFE Stack Dilution Bomb

One SAFE is manageable. Two is fine. Three is where things get complicated. Five is a Series A killer.

Here's a scenario I've seen play out more than once. Founder raises pre-seed from three angels:

• SAFE 1: $100K at $5M cap, 20% discount
• SAFE 2: $150K at $8M cap, 20% discount
• SAFE 3: $250K at $6M cap, 15% discount

Company lands a Series A term sheet at a $30M pre-money valuation. The founder thinks: great, we raised $500K, we're valued at $30M, this is a win. Then the lawyer runs the conversion math. Each SAFE converts at its own cap — $5M, $8M, and $6M respectively — not at $30M. The blended effective purchase price across all three SAFEs is around $5.5M. The company just sold a big chunk of itself at a weighted average 82% discount to the Series A price.

The Series A investor sees this and either reprices the deal to account for the dilution, demands the SAFEs be cleaned up before closing, or walks. I've seen all three outcomes. None of them are good for the founder.

The founders who avoid this problem keep their cap stack tight — same approximate cap level, no more than two SAFEs before pricing a round, and a spreadsheet that tracks every instrument from day one.

Jeff's 5 Rules for Using SAFEs and Convertible Notes Without Getting Burned

Rule 1: Use the YC template. Don't let lawyers customize it. The official Y Combinator SAFE template at ycombinator.com/documents is free, battle-tested, and recognized by every institutional investor. When your attorney starts proposing custom language, ask them what problem they're solving that the YC template doesn't. If they can't answer that clearly, stick with the standard. Custom SAFEs add legal cost, close time, and confusion — none of which helps you.

Rule 2: Never issue more than 2 SAFEs before pricing a round. The third SAFE is almost never worth what it costs you downstream. If you need more capital before you're ready to price a seed round, either get a second check from an existing SAFE investor (same terms, no new instrument) or use a convertible note bridge instead. Adding a third or fourth SAFE at different caps fragments your cap table and creates headaches that show up at exactly the wrong moment — when Series A due diligence is underway.

Rule 3: Keep your cap range tight. If your first SAFE is at a $5M cap, your second should be in the $6M–$7M range. It should not be at $12M. A wide cap spread means each SAFE converts at a drastically different price per share, which makes the share price calculation at Series A a mess. Tight caps — $5M to $7M range — keep the conversion math clean and signal to Series A investors that you ran a disciplined process.

Rule 4: Negotiate the option pool outside the cap. This single negotiation can save you 1–2 percentage points of dilution per SAFE. Most angel investors will accept it if you ask directly. If an investor refuses, you're not blocked from signing — just go in with your eyes open about the actual dilution you're taking.

Rule 5: Save convertible notes for Series A bridges. A convertible note shines as a 3–6 month bridge instrument when you're 90 days from closing a Series A and need runway to get there. At seed stage, the legal cost and timeline of a convertible note don't make sense. But at bridge stage, the maturity date creates exactly the forcing function you want — a clean deadline that motivates both sides to close the priced round.

Red Flags to Watch For

If an investor hands you a SAFE with custom language you haven't seen before, stop. Custom SAFEs signal either inexperience or an attempt to shift terms in their favor. Ask your attorney to compare it to the YC template line by line before you sign.

If you have five or more SAFEs on the books and haven't priced a round in 18 months, the clock is ticking on a dilution problem you'll have to explain to every future investor. Start consolidating or get to a priced round.

If an investor demands both a high cap ($50M on a pre-seed) AND a steep discount (25%), they're hedging in two directions at once. That's a sign they don't believe in the valuation they're agreeing to. I'd walk away from that deal.

And if you don't have a cap table spreadsheet tracking every SAFE, every option grant, and every pro-rata right in one place — fix that this week. You will be blindsided at Series A close, and that surprise is always expensive.

The Bottom Line

SAFEs are not better than convertible notes and convertible notes are not better than SAFEs. They solve different problems for different situations. SAFEs win on speed and legal cost at early seed stage. Convertible notes win on accountability and clarity when you're approaching a priced round.

The post-money SAFE trap is real — most founders underestimate their dilution by 1–3% per SAFE. Track every instrument obsessively, keep your cap stack clean, and price a round before you stack five SAFEs on top of each other. The founder who understands this math going in almost always negotiates better terms than the one who learns it during Series A due diligence.

Ask your attorney to run a full dilution model before your next SAFE close. Not after. Before.

Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.

This article is for informational and educational purposes only and does not constitute investment, legal, or tax advice. Always consult a qualified financial advisor, attorney, or tax professional before making investment decisions.